KORU Medical Systems demonstrates a robust top-line trajectory with 22.1% year-over-year revenue growth in 2026Q1, yet the company remains challenged by an inability to achieve operating leverage, evidenced by a -5.7% operating margin. While the firm maintains...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.01+155.6% vs -$0.02 | $12M+3.7% vs $12M |
Q2 2026 May 6, 2026 | -$0.02+0.0% vs -$0.02 | $12M+4.3% vs $11M |
Q2 2026 Mar 12, 2026 | -$0.01+50.0% vs -$0.02 | $11M+0.7% vs $11M |
Q4 2025 Nov 12, 2025 | -$0.02+33.3% vs -$0.03 | $10M-4.6% vs $11M |
KORU Medical Systems (NASDAQ: KRMD - Get Free Report) and Organigram Global (NASDAQ: OGI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Profitability This table compares KORU Medical
KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript
KORU Medical Systems NASDAQ: KRMD reported second-quarter revenue of $12 million, up 18% from a year earlier, as domestic patient starts, market-share gains and international demand supported growth. The company also said it achieved positive net income for the first time since 2019 and raised its full-year gross-margin outlook, while narrowing revenue guidance because certain international prefilled-syringe market launches are taking longer to develop than expected.
KORU Medical Systems, Inc. (KRMD) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to break-even earnings per share a year ago.
Benchmark KRMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for KORU Medical Systems, Inc. (KRMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.27 | $150.2M | -57.27 | 22.23% | -6.41% | -15.58% | — | |
| $59.96 | $3.05B | -249.81 | 14.88% | 1.85% | 2.14% | — | |
| $12.70 | $256.31M | 40.97 | 6.36% | 5.96% | 14.81% | — | |
| $80.58 | $1.84B | 31.98 | 13.53% | 25.02% | 16.42% | — | |
| $182.52 | $50.29B | 31.31 | 8.23% | 4.52% | 3.79% | — | |
| $23.49 | $12.13B | -13.42 | 5.72% | -9.27% | -16.67% | — |
KORU Medical Systems, Inc. (KRMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
KORU Medical Systems, Inc. (KRMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 5, 2026·SEC
Jun 30, 2026·SEC
Get notified when KRMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KORU Medical Systems, Inc. (KRMD) stock FAQ — growth, dividends, profitability & financials explained
KORU Medical Systems, Inc. (KRMD) reported $45.1M in revenue for fiscal year 2025. This represents a 2084% increase from $2.1M in 1999.
KORU Medical Systems, Inc. (KRMD) grew revenue by 22.2% over the past year. This is strong growth.
KORU Medical Systems, Inc. (KRMD) reported a net loss of $1.8M for fiscal year 2025.
KORU Medical Systems, Inc. (KRMD) has a return on equity (ROE) of -15.6%. Negative ROE indicates the company is unprofitable.
KORU Medical Systems, Inc. (KRMD) generated $0.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
